Podcasts about wegovy

The State of Hormone & Peptide Industry with Phil Vela Disrupting the health & wellness industry. (2:15) "It's that hard to do IT, so it's that easy to succeed once you've done IT." (2:48) What he did before he started Vita Bella, and the origins of the company. (5:00) The most applicable skills gained from his previous career. (7:41) Calling out the 'Grey Market' and its competition. (9:44) The state of the peptide industry and the fallout with Transcend. (15:54) Results & service. (25:23) Breaking down the Vita Bella membership package. (30:07) Businessman at heart. (33:34) Why he believes it should be illegal to prescribe GLP-1s by themselves. (35:13) Bad actors giving bad guidance. (43:33) His outlook for the future of the industry. (45:14) Will Ozempic and Tirzepatide ultimately bankrupt the United States? (53:27) The importance and value of having a trainer while on a GLP-1. (56:47) "I didn't build this business for money. I built it for a legacy!" (59:07) "Newer" peptides that have been impressed by. (1:03:16) Rapid fire: The best peptide for… (1:11:56) Related Links/Products Mentioned Visit Vita Bella for an exclusive offer for Mind Pump listeners! ** The first 50 signups will get a Vita Bella welcome box. You can finally achieve a top 1% all-around health at an affordable price! ** Get 20% off Kion at getkion.com/mindpump ** No code needed automatically applied at check out! ** MAPS Great 8 Launch - (Retail $127, Code: LAUNCH for 50% off!) ** Launch bonus include: MAPS GREAT 8 Nutrition Guide. ** Visit: http://mapsgreat8.com/  Mind Pump Store Mind Pump Hormones Facebook Private Forum GLP-1 Litigation: Compounder Sues Eli Lilly, Novo Nordisk Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Federal Court Tosses Lilly's Suit Against Strive Pharmacy: Jurisdiction Still Matters Mind Pump #2125: Heal Like Wolverine: BPC 157 with Dr. William Seeds Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Phil Vella – "Philly" (@phillyvz) Instagram Jay Campbell (@jaycampbell333) Instagram Rick Niemi (@gods.economy) Instagram Dr. William Seeds (@williamseedsmd) Instagram Peter Attia, M.D. (@peterattiamd) Instagram    

Today's episode of The Rizzuto Show might be the most “2026 energy” thing we've ever done — and that's saying something for a daily comedy show that thrives on chaos.First up: Liquid Death has created a $495 Bluetooth speaker urn called the “Eternal Playlist,” so when you're cremated, your ashes can keep vibing to Spotify. Yes, this is real. Yes, there's a stat about reducing your odds of haunting. And yes, Moon almost added it to his cart. We break down the marketing genius (or insanity), debate whether ghosts prefer classic rock or lo-fi beats, and ask the real question: who is this actually for?Then we dive headfirst into the wildest piece of funny celebrity gossip of the week. Bonnie Blue — an OnlyFans creator — claims she's pregnant after what she called a “breeding mission” involving 400 guys. Naturally, the internet immediately tagged Maury Povich. We discuss whether Maury should come out of retirement, whether we should host the paternity special ourselves in St. Louis, and how many DNA swabs King Scott is willing to sort through before lunch. It's entertainment gossip meets absurd reality TV, and somehow it only gets weirder.As if that wasn't enough, the Rock and Roll Hall of Fame nominations dropped, and the studio turned into a full-blown debate club. Wu-Tang Clan. Sade. Oasis. Mariah Carey. Does the Rock Hall still matter? Does any award show? Do artists secretly care even when they pretend they don't? It's sarcastic humor, passionate music arguments, and classic Rizz Show energy all rolled into one.This episode is peak funny podcast chaos — part comedy podcast, part music nerd fight, part daily humor therapy session for St. Louis and beyond. If you love pop culture commentary, comedy news, weird headlines, and the kind of daily show that spirals off topic in the best possible way, this one's for you.And yes… we still want to know who's buying that urn.Follow The Rizzuto Show → https://linktr.ee/rizzshow for more from your favorite daily comedy show.Connect with The Rizzuto Show Comedy Podcast online → https://1057thepoint.com/RizzShow.Hear The Rizz Show daily on the radio at 105.7 The Point | Hubbard Radio in St. Louis, MO.Heart Attack Grill 'spokesman' dies after apparent heart attackThe car with $8,660 in tickets that nobody will towWhat is sepsis, developed by UK woman who lost 4 limbs, after dog lick?What Does It Mean When a Dog Paws You? Decoding Your Canine's CommunicationDeath isn't the end: Meta patented an AI that lets you keep posting from beyond the graveNovo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027‘Plastic Eating' Trend for Weight Loss Is Going Viral in ChinaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Een jaar lang scheten aandeelhouders van Wolters Kluwer in hun broek voor wat er daar aan zat te komen. Het verdienmodel van het databedrijf zou onderuit gehaald worden door AI-bedrijven die het allemaal beter en sneller gaan kunnen. Waardoor de beurskoers in een jaar tijd met ruim 60 procent daalde. Alleen... dat blijkt nu behoorlijk paniekvoetbal. De kwartaalcijfers laten namelijk een ander beeld zien. Omzet en winst stijgen. En Wolters Kluwer bewijst het ongelijk van beleggers nog even extra: want vooral de cloud-activiteiten groeien hard, met 15 procent. Een afscheid in stijl voor ceo Nancy McKinstry, wiens laatste kwartaal dit was. Deze aflevering kijken we of aandeelhouders die zijn vertrokken, nu reden hebben om terug te keren.Hebben we het ook over een ander beursdrama, maar dan in Denemarken. Dat van Novo Nordisk. De maker van onder meer Ozempic had een voorsprong met hun afvalmedicatie, maar werd keihard ingehaald door de concurrentie. En zag het aandeel zelf op een crashdieet gaan. Van het meest waardevolle Europese beursbedrijf, naar een van de beurslosers. Maar die tijd is misschien wel voorbij, want Novo Nordisk heeft iets verzonnen. Het gaat de prijzen halveren.Hoor je ook meer over de State of the Union. Trumps speech heeft een record gebroken. Nog nooit duurde dat politieke praatje zo lang. Maar of het ook een beetje inhoudelijk was, dat bespreken we deze aflevering. Zo wil Trump de inkomstenbelasting inruilen voor.... tarieven! Te gast: Martine Hafkamp van Fintessa Vermogensbeheer BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

Send a textThis episode unpacks Novo's aggressive price cuts, Lilly's head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war.00:00 – Cold Open: Lilly vs Novo Shock TimingDave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match.03:20 – Novo Nordisk Price Cuts ExplainedDeep dive into Novo's plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning.07:25 – Tirzepatide vs Semaglutide Head to Head TrialBreakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially.11:55 – Market Reaction and Strategic ImplicationsDiscussion of stock movement, competitive signaling, and how Novo's pricing move may blunt Lilly's trial victory.14:25 – Novo Triple Agonist Data DropsShift into Novo's early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists.16:00 – Comparing Novo's Triple to RetatrutideAnalysis of weight loss percentages versus Lilly's retatrutide data and the caution required when comparing across trials.18:15 – The Triple Agonist EraBroader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term.20:00 – Clinical Trial Results vs Real World RealityReminder that clinical trial outcomes do not automatically translate to everyday patient experience.22:30 – Data Refresher on Allurion Ballon ApprovalQuick recap of the headline numbers and strategic landscape as innovation and pricing Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Bob talks about the extra NYS DMV fee for upstate transit funding, Norvo Nordisk to cut prices for Ozempic and Wegovy, the search for Nancy Guthrie continuing, David Robinson released after crash with RTS bus after fleeing police, and Bob takes calls.

In this episode, Gianna Beasley interviews Aja Beckett, the founder of Shotsy, a companion app for individuals on GLP-1 medications. Aja shares her personal journey with obesity and the challenges she faced before discovering GLP-1s. We dive into the struggles of weight management, the creation of the Shotsy app, its features, and the importance of community support. Shotsy is a mobile health tracking app specifically designed for people using GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, Semaglutide, and Tirzepatide. It helps users monitor their injection schedule, side effects, and progress toward goals like weight loss or health improvements. Aja discusses the app's freemium model, ensuring accessibility for all users, and discusses the significance of building trust within the GLP-1 community.Download Shotsy in the App Store on Apple or Android!

Are you worried GLP-1 medications will make coaches obsolete? Medications like Ozempic, Wegovy, and Mounjaro are changing the weight loss conversation, but they're not replacing the work coaches do. In fact, they're making behavior change coaching more essential than ever.In this episode, Dr. Kasey Jo Orvidas breaks down what GLP-1s actually do, why 50-75% of users stop taking them within a year, and how coaches can support clients using these medications while staying ethically grounded and professionally valuable.You'll learn:What GLP-1 medications actually do (and what they don't teach clients about behavior change, mindset, or long-term habits)Why people still need coaches even when medication accelerates weight lossHow to navigate the ethical dilemma of posting client transformations when GLP-1 use is involvedSix ways coaches can support clients on GLP-1s, from muscle preservation to managing identity shifts and shameWhy the future of coaching requires more psychology, communication skills, and mindset work (not less)Watch the full episode on YouTube: https://youtu.be/gKmAYVkVbDgRegister for my FREE 3-Day Training: The Coaching CodeConnect with me on Instagram! Grab 5 Free Lessons in Mindset and Behavior Change Coaching [HMCC WAITLIST]LEAVE A REVIEW, WIN A WORKSHOP! After you leave your review, take a screenshot and upload it to this form to be entered to winWant me to answer your questions on my next Q&A episode? Drop your questions here!Related Topics: GLP-1 medications for weight loss, Ozempic and coaching, Wegovy and fitness coaches, coaching clients on weight loss medication, behavior change coaching, mindset coaching with GLP-1s, ethical coaching practices, client transformation ethics, future of health coaching, weight loss medication support, coaching industry trends, muscle preservation on GLP-1s, sustainable weight loss habits

The Science Behind the New Wegovy Pill (with Novo Nordisk's Dr. Jason Brett)What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor are joined by Dr. Jason Brett of Novo Nordisk to break down the science behind the newly approved Wegovy pill. They talk about what it takes to deliver a peptide medication orally, what the dosing and day-to-day routine really look like, and why access and pricing remain such a big part of the story. The conversation also zooms out to the bigger point: treating obesity is about improving health outcomes—like liver and cardiovascular risk—not just weight.Key TakeawaysOral semaglutide requires specific formulation technology to survive the stomach and be absorbed at a meaningful level.The “30-minute rule” isn't random—it's part of how the pill has a chance to work as intended.Treating obesity is about improving health outcomes (like liver and heart risk), not just “moving a number on a scale.”Pricing and access shape who can actually benefit, even when the science is strong.Calorie-restriction messaging can backfire for people already dealing with metabolic adaptation and under-nutrition.Notable Quote"Fat Science has no financial relationship with Novo Nordisk. No sponsorship. No consulting fees, no affiliate arrangements. Zero." — Mark WrightLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Queda de cabelo, fraqueza e intestino parado. Vamos falar do preço metabólico da falta de nutrientes e como reverter isso.Bônus: Suplementos que podem ajudar para quem estiver usando GLP-1Se você está usando análogos de GLP-1 (como Ozempic, Mounjaro, Wegovy) para emagrecer, é provável que esteja feliz com os números caindo na balança, mas... exausta na vida real.Sabe aquela sensação de corpo pesado? De fraqueza para subir um lance de escada? Aquele cabelo caindo mais que o normal e uma “névoa” mental que não passa?Não, não é “coisa da sua cabeça”. E não vale colocar na conta da menopausa também não. E não, não é o preço que você precisa necessariamente pagar para ser magra — se souber fazer direito.Compreenda por que emagrecer sem suporte metabólico leva à magreza frágil, ao efeito rebote e ao colapso da vitalidade. E, principalmente, como usar essas medicações do jeito certo, com estratégia, nutrição e proteção muscular.Neste episódio, você vai aprender:Por que estar magra não significa estar saudávelComo a perda de apetite leva ao modo racionamento metabólicoO risco real da perda muscular silenciosa com GLP-1Por que perder músculo acelera o envelhecimento e o efeito reboteO impacto das “canetinhas” no intestino, digestão e SIBOComo fazer o uso correto dos GLP-1 com suporte metabólicoEstratégias de proteína, treino e suplementação para preservar energiaComo reverter cansaço, fraqueza, queda de cabelo e intestino paradoMeu livro Perimeno Quê? O manual que eu queria ter tido quando eu passei pela perimenopausa já está disponível para vendas.

What if weight loss isn't about discipline—but about biology? In this episode of Healthy Looks Great on You, Dr. Vickie welcomes Dr. Suzanna Chatterjee-Morris, a board-certified OB-GYN and obesity medicine physician, for a fascinating conversation about GLP-1 medications and what they really do inside the body. Together, they take listeners to mini medical school to break down: What GLP-1 medications are and how they affect insulin resistance and metabolism Why weight gain is often a medical issue—not a personal failure How GLP-1s are being used beyond weight loss, including PCOS, infertility, fatty liver disease, sleep apnea, and cardiovascular health What the research shows about long-term benefits and reduced all-cause mortality Common concerns like muscle loss, weight regain, and “Ozempic face” Why nutrition, protein intake, and exercise are essential when using these medications Dr. Chatterjee also explains the concept of weight “set point,” why stopping these medications too soon often leads to regain, and how GLP-1s work best when paired with sustainable lifestyle changes—not willpower alone. If you've been curious or confused about Ozempic, Wegovy, Zepbound, or similar medications, this episode offers clarity, evidence, and reassurance—without hype or shame.

In den USA nehmen inzwischen rund 12 % der Erwachsenen GLP-1-Medikamente wie Wegovy, Ozempic oder Mounjaro – ursprünglich zur Behandlung von Diabetes entwickelt. Und der Trend beschränkt sich längst nicht mehr nur auf die USA: Weltweit greifen Millionen Menschen zu den Abnehmspritzen. Das Prinzip ist simpel: weniger Appetit. So sollen Gewichtsverluste von 14 bis 22 % möglich sein. Unser Dauerpraktikant hat es ausprobiert…

Millions of Americans are turning to GLP-1 weight loss medications like Ozempic and Wegovy. But here's the question few are asking: What happens when you stop? Research shows that many people regain a significant portion of the weight within a year of discontinuing GLP-1 medications. In some studies, participants regained as much as two-thirds of the weight they lost. On this episode of The Exam Room, Chuck Carroll sits down with world-renowned obesity researcher James Hill, PhD to unpack the real story behind long-term weight management after GLP-1 medications. Dr. Hill is a pioneering scientist and former president of The Obesity Society and The American Society for Nutrition. Along with Dr. Holly Wyatt, he co-authored the new book Losing the Weight Loss Meds: A 10-Week Playbook for Stopping GLP-1 Medications Without Regaining the Weight. In this conversation, you'll learn: • Are GLP-1 medications meant to be long-term? • What happens inside the body when you stop taking them • Why so many people regain weight after discontinuing • The 10-week transition strategy for maintaining weight loss • The three types of weight regain—and how to avoid each • How to quiet food noise and cravings naturally • Daily habits that can replace the work of GLP-1 medications Chuck also shares his personal perspective on long-term weight loss success, including: • What he's learned after weight loss surgery • The lifestyle shifts that made his results sustainable • And what he wishes he knew before surgery that he knows now If you're considering GLP-1 medications, currently using them, or thinking about stopping, this episode could change how you approach weight maintenance forever.

U.K. authorities on Thursday arrested Andrew Mountbatten-Windsor on suspicion of "misconduct in public office." Police had previously said they were investigating whether the former prince sent confidential trade documents to the late sex offender Jeffrey Epstein. Liz Stein, a survivor of Epstein's abuse and an anti-trafficking advocate, joins us.Then, Meta's Mark Zuckerberg appeared in a Los Angeles court on Wednesday to defend his company against a lawsuit that alleges social media harms children. LA Times reporter Sonja Sharp breaks down the trial so far.And, GLP-1 medications could help treat alcohol and drug addiction, experts say. Addiction specialist Dr. Mark S. Gold explains how medications such as Ozempic and Wegovy are prompting "a reconceptualization of addiction itself."Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In this conversation with Dr. Wendy Oliver-Pyatt, a board-certified psychiatrist specializing in eating disorders and founder of Within Health and Galen Hope treatment centers, Karena explores the life-threatening reality of eating disorders as serious mental illnesses that claim one life every 52 minutes in America. Dr. Oliver-Pyatt explains the biopsychosocial foundations of eating disorders, shares her personal journey from ballerina to eating disorder specialist, and discusses the warning signs in athletes and high achievers. She reveals the controversial truth about GLP-1 medications and eating disorder risk, and provides actionable tools for reframing your relationship with your body through self-compassion and intentional self-care practices.How do you stop fighting your body and start healing your relationship with food, weight, and self-worth?Understanding that weight stigma is trauma opens the door to compassion—and real recovery.(01:13) The Deadliest Mental Illness You've Never Heard OfEating disorders kill one person every 52 minutes in AmericaWhy they aren't classified with "serious" mental illnesses despite being more lethal than manyThe confusion between societal pressure and actual mental illness diagnosisUnderstanding the biopsychosocial foundation: biological, psychological, social, and spiritual factors(04:47) From Ballerina to Eating Disorder PsychiatristGrowing up as the child of a Holocaust survivor with a mildly autistic motherHow ballet and puberty collided to create impossible body standardsThe danger of narrow frameworks about what's "acceptable" in our bodies(18:32) Athletes, Perfectionism & the "Healthy" Eating TrapWhy high-achieving athletes and fitness enthusiasts face elevated eating disorder riskThe difference between disordered eating behaviors and diagnosable eating disordersHow orthorexia disguises itself as "clean eating" or "wellness"Warning signs to watch for in competitive sports and fitness culture(32:47) What Real Treatment Looks LikeThe biopsychosocial-spiritual treatment model that addresses all aspectsHow nutritional rehabilitation and medical stabilization work togetherFamily-based treatment approaches for adolescents and young adults(47:36) The GLP-1 Controversy: Ozempic, Wegovy & Eating Disorders"It's asinine there's no eating disorder warning"How rapid weight loss medications trigger and worsen eating disorders, especially in teensThe danger

“That's the thing that's maybe getting lost in some of the fear mongering around it is that, it's not the easy way out. It doesn't mean that you don't have to do the work. It means that when you do the work, the work actually makes the difference.” —Aja BeckettFood noise can sit in the back of the mind all day, from planning the next meal at breakfast to carrying quiet shame after every snack. In a culture that moralizes weight and labels bodies as failures, real medical treatment for obesity often gets buried under hot takes about shortcuts and cheating. This conversation brings the lived reality of GLP-1 medication into the light, with honesty about both relief and responsibility.Aja Beckett shares decades of struggling with obesity, endless diets, and that constant mental hum around food, then walks through how starting a GLP-1 weight loss drug shifted cravings, energy, and hope. Her experience led to building Shotsy, a companion app that tracks doses, side effects, and progress for people on GLP-1 medications.Press play to hear how this new class of medications is reshaping daily life, mindset, and digital tools around obesity care, including:What GLP-1 drugs like Ozempic and Wegovy actually do in the bodyThe difference between “food noise” and genuine hungerWhy weight loss drugs are not a lazy shortcut or moral failureHow mental health, cravings, and compulsive behaviors often change on GLP-1sThe cost, access, and safety concerns around weight loss injections and pillsHow a GLP-1 tracking app grew from one person's spreadsheet into a fast-growing productWhat long-term obesity treatment and maintenance can realistically look likeConnect with Heather:WebsiteLinkedInInstagramFacebookYouTubeEpisode Highlights:01:11 Meet Aja Beckett: Founder of Shotsy & GLP‑1 Success Story04:43 Discovering Ozempic & a Difficult Doctor's Visit07:35 Beyond Weight Loss: GLP‑1, Mental Health & Addictive Behaviors10:43 Losing 90 Pounds: From Obesity to Healthy BMI13:30 Do You Still Have to Eat Healthy & Work Out on GLP‑1?16:21 When the Food Noise Stops: First Days on GLP‑119:37 Super Bowl Snacks, Portion Control & Balanced Indulgence22:12 Body Dysmorphia in Bigger & Smaller Bodies26:00 Safety vs Affordability: Regulation, Shortages & DIY Risks32:09 Introducing Shotsy: The GLP‑1 Companion App Idea39:50 Why Tools Like Shotsy Matter for Accountability & Tracking42:21 GLP‑1 Isn't the “Easy Way Out”: Doing the Work & Seeing ResultsResources:

Dhruv Khullar, practicing physician, associate professor of health policy and economics at Weill Cornell Medical College and contributing writer at The New Yorker, talks about the effect GLP-1 drugs, like Ozempic, are having on curbing addictions and what researchers are studying about that phenomenon.Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images

Are medications solving the root of metabolic disease — or just masking it? In this powerful episode that started as a Instagram LIVE, I break down what you're not being told about the most commonly prescribed drugs for blood sugar, cholesterol, and weight loss: GLP-1s (Ozempic, Wegovy), statins, and Metformin. I help you unpack: What these medications actually do (mechanisms of action) The real data behind their risk reduction claims How statins may suppress natural GLP-1 production Why GLP-1s cause significant muscle loss, not just fat loss Why Metformin doesn't reverse insulin resistance More importantly, I walk you through what does restore metabolic health — including a system that's helping real people normalize labs, lose weight, and feel better without long-term prescriptions. What You'll Learn: The surprising truth about how statins impact your gut hormones Why insulin resistance — not cholesterol — is the real root cause How GLP-1 drugs work and what happens when you stop them The 3-step system to support blood sugar and cholesterol naturally How to evaluate your labs beyond A1C and LDL Resources Mentioned: Join my 90-Day Insulin Reset: Comment RESET on Instagram or Facebook and I'll DM you the link- https://shanahussinwellness.com/programs-courses/reset/ Feel Great Nutraceuticals: The first step to restoring insulin and liver function- https://shanahussinwellness.com/programs-courses/feelgreat/ Connect with Shana: Instagram: @shana.hussin.rdn Website: shanahussinwellness.com Facebook: Shana Hussin Wellness

Send a textWegovy's new 7.2 mg dose—three times higher than the current max—has just been approved in the EU, with U.S. approval expected soon. But now that Wegovy matches Zepbound on weight loss, the real question isn't which drug helps you lose more weight—it's which one treats your underlying metabolic disease more effectively.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Part 2 picks up right where Part 1 ends—and goes deeper into what people are really wondering: What's safe? What's real? And who can I trust? Jamie and Jaclyn  talk about how misinformation spreads, why some people experience negative outcomes (often by skipping proper dosing, labs, and provider follow-ups), and why these wellness tools are most powerful when used with structure and medical guidance. You'll also hear a transformation story that's bigger than weight—one that changed energy, marriage, medications, and an entire family's trajectory. This episode is a reminder that the first step isn't dramatic… it's brave. www.YourHealth.Org

Skinny is in, and it doesn't help when the drugs that help us get there are set to get cheaper.Whether it's Ozempic or Wegovy, the cost of shrinking doesn't end with what you pay at the pharmacy. It bleeds into your everyday interactions - both with others and by yourself. And unless your results are being guided by a dietician or medical provider, who's to say how sustainable pay-as-you-go weight-loss actually is?Host Maria Kestane speaks to writer Brianne Cail to unpack her journey using weight-loss drugs, and the give-and-take at the cost of her wellbeing thanks to the cost of drugs. The two also discuss what safeguards Health Canada could implement to help patients move through prescribed weight-loss and weight management. We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstory.bsky.social on Bluesky

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news on Ozempic from medical breakthroughs to real-life health impacts.Recent Cochrane reviews commissioned by the World Health Organization show that Ozempic, or semaglutide, leads to about eleven percent average weight loss after six to eighteen months in people with obesity, outperforming placebo in eighteen trials with nearly twenty-eight thousand participants. Tirzepatide, like Mounjaro, achieves even more at sixteen percent, while liraglutide offers four to five percent. These glucagon-like peptide-one drugs mimic a hormone that slows digestion and boosts fullness, originally for type two diabetes but now key for weight management with diet and exercise.Cochrane researchers note benefits persist during treatment but highlight gaps: most trials were industry-funded, long-term safety data is limited, and side effects like nausea affect many, with some dropping out. No clear edge on heart events or death versus placebo yet.A Rutgers Health study in the Journal of Medical Internet Research analyzed sixty online reviews and found sixty-seven percent of users report weight loss, less appetite, or fewer cravings, making them stick with it despite nausea or vomiting in sixty-two percent. Lead author Abanoub Armanious says everyday experiences show benefits often outweigh gut issues for motivated users. Bariatric expert Mir Ali adds diarrhea or pain prompts more quits than nausea.Newer buzz includes Ozempic face: rapid fat loss causes gaunt cheeks, per a Gujranwala Medical College analysis and American Academy of Facial Plastic and Reconstructive Surgery survey, boosting filler demand by fifty percent. Weight regain post-treatment is common, stressing lifestyle pairing.Wegovy now offers semaglutide pills like Rybelsus, matching injections for seventeen percent loss with changes, per Prisma Health's Eva Wolf.Listeners, blend these tools with habits for lasting wins. Thanks for tuning in—subscribe for more updates. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

 Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.comHave you ever wondered which weight loss medication is actually right for you? With so many options out there—new GLP-1 medications like Wegovy and Zepbound, oral versions hitting the market, and older prescriptions—it can feel totally overwhelming.In this episode, we break it all down: how much weight you might realistically lose, how other health conditions factor in, cost considerations, who should avoid certain medications, and even how combination therapy can sometimes make sense.Over the years, I've covered these topics in different ways. One of my favorite episodes was with Dr. Angela Fitch, where we explored all the available medications at that time. Since then, new therapies like Zepbound and oral Wegovy have emerged, changing the landscape even more. This episode isn't meant to replace a one-on-one conversation with an obesity expert—that's still the gold standard—but it gives the information you need to start thinking about what might fit your goals, your body, and your lifestyle.By the end, you'll have a clearer picture of how these medications work, who they help most, and how to approach the decision thoughtfully and safely. Obesity is a medical condition, and like any condition, it deserves expert care—so let's dive into your options.Topics Covered:How Much Weight Can You Really Lose on GLP-1 Medications?The Other Medications That Still Play a Role in Weight LossWegovy vs. Zepbound: How Much Weight Loss Do You Actually Need?Why Weight Loss Is a Struggle—and How the Right Medication Makes the DifferenceResults Matter—But So Does the Price TagWho Should Avoid Certain Weight Loss MedicationsChoosing the Right Weight Loss Medication: Pills, Injections, and Personalized ApproachesDo You Really Need More Weight Loss?By the end of this episode, you'll have a clear understanding of the different weight loss medications, how they work, who they help most, and what to consider when choosing the right approach for your goals and health.For a deeper dive into each medication, real-world results, and expert insights on tailoring a plan that's safe, sustainable, and effective, the full episode is ready for you—it's packed with everything you need to make an informed decision about your weight loss journey.Referenced Episodes:Can a test tell me if Wegovy or Zepbound will work for me? With Dr.Andres Acosta of PhenomixMedications for Weight Loss with guest, Dr. Angela Fitch,Phentermine and Qsymia - What You Need to Know About These Weight LossOral Wegovy: All You Need to Know About This New Medication, with Joseph ZucchiConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

במאה ה-20 תעשיית המזון וההסעדה נבנתה על ארכיטקטורה של דחפים, על היכולת של המלח, הסוכר והשומן לעקוף את מנגנוני השובע שלנו ולייצר מעגל אינסופי של "עוד". אבל בשנים האחרונות מתפשטת בעולם טכנולוגיה חדשה שמציעה למשתמשים חומת מגן כימית שמשתקת את הרעש, את התשוקה. הטכנולוגיה הזו מכניסה תוכן חדש לשיחה שמתנהלת בין הלבלב לבין אזור במוח שנקרא היפותלמוס, והתוכן הזה גורם לאלו שמשתמשים בתרופות שמבוססות עליה, Ozempic, Wegovy, Mounjaro ותרופות אחרות, להרגיש שהם... שבעים.סקרים שנערכו בסוף 2025 הראו שכ-1 מכל 8 מבוגרים בארה"ב התנסה בתרופות האלו ויש וההערכות לפיהן עד לשנת 2030 הן יהפכו לקטגוריית התרופות הנמכרת בהיסטוריה של עולם הרפואה.כולנו עסוקים בבינה מלאכותית אבל המהפכה השקטה ביותר של המאה ה-21 לא מתרחשת במשרדי חברות הטכנולוגיה שעמק הסיליקון ובתוך המחשבים שלנו - היא מתרחשת בתוך הגוף שלנו והיא נשענת על טכנולוגיה רפואית. אבל בדומה למהפכה הרועשת, ההשפעות של המהפכה השקטה הן נרחבות, עמוקות ומפתיעות.קישורים:מחקר: ירידה של 8% בהוצאות בסופרמרקט בקרב נוטלי תכשירי GLP-1https://news.cornell.edu/stories/2025/12/ozempic-changing-foods-americans-buyהפרסומת ל-Wegovyhttps://www.youtube.com/watch?v=7Y6zH5bm2eYספר: על הקשר שבין מזון מהיר והמכונית הפרטיתhttps://www.amazon.com/Fast-Food-Roadside-Restaurants-Automobile/dp/0801861098

Today I'm joined by Dr Courtney Raspin, a Chartered Counselling Psychologist and Clinical Director of Altum Health, a specialist eating disorders and mental health clinic in London. Courtney has over 25 years of clinical experience, including a decade in one of the NHS's largest eating disorder services.She's just co-authored a book called The Weight Loss Prescription with psychiatrist Dr Max Pemberton (available 26th Feb!) - a book about the psychology of GLP-1 weight loss medications like Wegovy and Mounjaro. Given her background in eating disorders, Courtney has a nuanced perspective on weight loss medications, which I think is really important to hear.If you're in eating disorder recovery and feeling unsettled by the rise of GLP-1 medications… if you've noticed feelings of jealousy, confusion or fear around them… or if you're trying to understand where health support ends and diet culture begins, this conversation is for you.Key Takeaways:How Courtney's work in eating disorders shaped her approach to weight managementThe warning signs of high drive for thinnessWhy weight loss doesn't automatically improve body imageThe difference between body neutrality and body positivityWhy GLP-1 medications aren't inherently harmfulThe risks of unregulated access, online prescribing, and counterfeit medicationThe various causes of “food noise” and why GLP-1 medications may helpWhat psychological support in weight management actually involvesCourtney's guidance on GLP-1s and eating disorder recoveryTimestamps:00:00 Courtney's journey into weight management05:00 Body neutrality and realistic body image work08:30 Understanding GLP-1s: benefits, risks and misconceptions12:00 Food noise and why context matters16:00 The psychological work behind lasting change21:00 Health vs the thin ideal27:00 Tensions within the ED field and professional responses31:30 What to consider before starting GLP-1s34:30 Courtney's book and final adviceResources & LinksFollow @drcourtneyraspin on InstagramConnect with Us:Subscribe to the Full of Beans PodcastFollow Full of Beans on InstagramCheck out our websiteListen on YouTube⚠️ Trigger Warning: Mentions of eating disorders (anorexia, bulimia, binge eating), restriction, weight loss, GLP-1 medications, and body image. Please take care when listening.If you enjoyed this episode, don't forget to subscribe, rate, and share the podcast to help us spread awareness.Sending positive beans your way, Han

Au sommaire : La ministre de l'Agriculture, Annie Genevard, dénonce le "chantage mortifère" de certaines enseignes de distribution qui réclament des baisses de prix dans le cadre des négociations commerciales.Le gouvernement va réduire les aides à l'apprentissage, en baissant la prime à l'embauche de 500 euros pour les jeunes issus de l'enseignement supérieur, dans le but d'économiser 200 millions d'euros.Le ministre de l'Économie, Roland Lescure, annonce un investissement de 200 milliards d'euros pour moderniser le réseau de distribution électrique français.*Stellantis va relancer la production de moteurs diesel sur plusieurs de ses modèles en Europe, malgré son engagement pour l'électrification.Le brevet du principe actif contenu dans les traitements anti-obésité Ozempic et Wegovy arrive à expiration dans plusieurs pays, ce qui devrait favoriser l'arrivée de génériques et une baisse des prix.Aux États-Unis, la démission de la responsable de l'application des lois antitrust au ministère de la Justice soulève des soupçons de favoritisme envers les grandes entreprises.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

במאה ה-20 תעשיית המזון וההסעדה נבנתה על ארכיטקטורה של דחפים, על היכולת של המלח, הסוכר והשומן לעקוף את מנגנוני השובע שלנו ולייצר מעגל אינסופי של "עוד". אבל בשנים האחרונות מתפשטת בעולם טכנולוגיה חדשה שמציעה למשתמשים חומת מגן כימית שמשתקת את הרעש, את התשוקה. הטכנולוגיה הזו מכניסה תוכן חדש לשיחה שמתנהלת בין הלבלב לבין אזור במוח שנקרא היפותלמוס, והתוכן הזה גורם לאלו שמשתמשים בתרופות שמבוססות עליה, Ozempic, Wegovy, Mounjaro ותרופות אחרות, להרגיש שהם... שבעים.סקרים שנערכו בסוף 2025 הראו שכ-1 מכל 8 מבוגרים בארה"ב התנסה בתרופות האלו ויש וההערכות לפיהן עד לשנת 2030 הן יהפכו לקטגוריית התרופות הנמכרת בהיסטוריה של עולם הרפואה.כולנו עסוקים בבינה מלאכותית אבל המהפכה השקטה ביותר של המאה ה-21 לא מתרחשת במשרדי חברות הטכנולוגיה שעמק הסיליקון ובתוך המחשבים שלנו - היא מתרחשת בתוך הגוף שלנו והיא נשענת על טכנולוגיה רפואית. אבל בדומה למהפכה הרועשת, ההשפעות של המהפכה השקטה הן נרחבות, עמוקות ומפתיעות.קישורים:מחקר: ירידה של 8% בהוצאות בסופרמרקט בקרב נוטלי תכשירי GLP-1https://news.cornell.edu/stories/2025/12/ozempic-changing-foods-americans-buyהפרסומת ל-Wegovyhttps://www.youtube.com/watch?v=7Y6zH5bm2eYספר: על הקשר שבין מזון מהיר והמכונית הפרטיתhttps://www.amazon.com/Fast-Food-Roadside-Restaurants-Automobile/dp/0801861098מקווים שנהנתם ואם כן אל תשכחו לדרג ולעקוב אחרי הפודקאסט.אל תשכחו להצטרף לניוזלטר השווה שלנו בלחיצה כאן. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

Now that Wegovy has created a shot for kids to take when they are over weight Dr. Franco is breaking down all the facts for us. 

On Food Talk with Dani Nierenberg, Dani speaks with Ndidi Okonkwo Nwuneli, the President and CEO of the ONE Campaign. They discuss how the dismantling of the U.S. Agency for International Development has impacted the African continent, the opportunities this shifting landscape creates for the emergence of African-led solutions, and the innovative women spearheading food and agriculture systems transformation. Plus, hear about the recent extension of the African Growth and Opportunity Act, severe storm damage in Portugal and Spain causing hundreds of millions of euros in agricultural losses, new recommendations from the World Resources Institute for retailers to help reduce household food waste, and a looming strike at the JBS meatpacking plant in Colorado over alleged inhumane working conditions. Dani also discusses GLP-1 drugs like Ozempic and Wegovy, noting their complex and under-researched impact on people with eating disorders, including both potential benefits and serious risks. While you're listening, subscribe, rate, and review the show; it would mean the world to us to have your feedback. You can listen to "Food Talk with Dani Nierenberg" wherever you consume your podcasts.

Injectable peptide therapy, a controversial wellness trend that caught fire online in 2025, shows no signs of slowing down in 2026 despite an overwhelming lack of safety data. Peptides, especially “research peptides” like BPC-157 and TB-500, have been hailed by famous podcasters, biohackers, and longevity gurus as a miracle cure for just about anything that ails you, from torn ligaments and gut issues to curbing wrinkles and dull skin. There are several well-studied, FDA-approved peptides available today, such as insulin and GLP-1s like Ozempic and Wegovy, but that's just a sliver of the peptide pie. There are thousands more with glowing online reviews, but scant scientific data, that can be procured online or through longevity clinics. Mixes of various peptides, called “peptide stacks,” often come with clever names like the ‘'wolverine stack' or ‘glow protocol', while others have earned names like ‘Barbie peptide' for their ability to tan the skin without the sun. These popular stacks are not FDA-approved, so they're distributed online as 'research peptides' that are meant for in-lab research, not human use — a workaround for their gray market status. To find out more, host Lexy Lebsack sat down with two experts on the topic. First up was NYT's David Dodge (8:42), who walked us through the rise of peptide therapy online. He published an article for NYT in November titled “The internet loves peptide therapy. Is it really a miracle cure?” Lebsack also interviews McGill's Jonathan Jarry (29:35), who wrote an article in late 2023 — well ahead of a rush of online articles — called “The human lab rats injecting themselves with peptides.” Jarry walks us through the hard science, and lack thereof, of many popular stacks, ahead.

Silver, Gold and Crypto (oh my) Hang on – Wild ride here Superbowl, Olympics- Wait until you hear about the CAPex spending! Shakeup in Dietville PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Silver, Gold and Crypto (oh my) - Need a stock for CTP - Hang on - Wild ride here - Superbowl, Olympics- Wait until you hear about the CAPex spending! - Shakeup in Dietville Markets - Massive moved during the week - - Bitcoin clipped $60k before rebounding - DJIA tops 50,000 for the first time - Wait until you hear about the CAPex spending! - CAT == 1,100 points on the DJIA in 2026 Superbowl and Superbowl ads - Game review - Any ad stick out? - $10M per ad this year - Half Time with Bad Bunny? - Anthropic busting on OpenAi Last Week! - Massive moved - quick calc showed that about $1T was wiped from market caps in the sell-off, particularly in tech names. - HOWEVER - Friday alone is estimated to have added $1.5T to market cap AI Ripping Through - Plenty of names getting cooked over AI announcements - First it was the software companies - Now there are names in legal and finance that got clocked - Today - Altruist.ai can do tax planning and that hurt companies in financial space Earnings Season Update - Reporting so far: 59% of S&P 500 companies have reported Q4 2025 results. - Beat rate: 76% have topped EPS estimates (vs. 5-yr average: 78% (slightly lower) vs. 10-yr average: 76% (in line) - Magnitude of beats (aggregate): earnings are 7.6% above estimates vs. 5-yr average: 7.7% (about the same) vs. 10-yr average: 7.0% (a bit better) - Nothing great,  like Goldilocks Earnings Highlights - Palantir (PLTR): Reported strong Q4 results early in the week , beating estimates with revenue ~$1.41B (vs. ~$1.33B expected) and EPS $0.25 (vs. $0.23). Guidance for 2026 was upbeat (~61% revenue growth). Shares rallied sharply initially (~7–11% post-earnings), but gave back some gains amid broader tech volatility (e.g., down ~11–22% in parts of the week from peaks). - AMD: Reported mid-week, beating EPS (~$1.53 vs. lower expectations) with solid data center growth (~39%). However, Q1 guidance disappointed relative to high expectations in the AI chip space. Shares sank dramatically — down ~15–17% the next day, with some reports noting up to 20%+ drops at points, contributing to broader chip sector pressure. - Alphabet (GOOGL/GOOG): Reported beating on revenue (~$113.8B) and EPS (~$2.82), with strong core performance. But capex guidance for 2026 ($175–$185B, roughly double prior levels) sparked AI spending worries. Shares dipped post-earnings (down ~0.5–5% initially, flat to lower the next day, with some volatility pulling it below key moving averages). - Amazon (AMZN): Reported after hours on February 5, with mixed results — EPS ~$1.95 (narrow miss vs. ~$1.97 expected), but solid overall. The big negative was a surprise $200B capex forecast for 2026 (well above expectations), tied to AI/cloud buildout. Shares plunged sharply — down ~7–10% in after-hours/extended trading, with Friday moves around -5–8% in some sessions. Recent Tech CAPEX announcements - Amazon (AMZN) — Guided to approximately $200 billion in capex for 2026 (a massive jump from ~$125–131 billion in 2025, with ~80% likely AI-related per analyst commentary). This was the largest single-company figure and a major surprise, contributing heavily to the week's "wild" reactions. - Alphabet (GOOGL/GOOG) — Guided to $175–185 billion in capex for 2026 (roughly double the $91 billion spent in 2025, far above analyst expectations of ~$115–119 billion). Emphasis was on AI compute capacity, servers, data centers, and networking to meet demand for Gemini and cloud services. - Meta Platforms (META) — Guidance from late January (but heavily discussed last week): $115–135 billion for 2026 (up significantly from ~$70–72 billion in 2025, potentially an ~87% increase). - Microsoft (MSFT) — No new full explicit 2026 guidance in early February (fiscal year runs July–June), but recent quarterly run-rate and analyst projections put it around $97–145 billion (with some sources citing ~$105 billion or higher based on Q2 spending trends and signals of continued growth from prior levels of ~$88 billion in FY2025). ------!!!!Combined 2026 capex projected at $635–665 billion (low/high ends) or up to $650–700 billion in some reports — a ~60–74% increase from their collective ~$381 billion in 2025. Market Reaction from all of this.... - Markets were a bit spooked on the Anthropic announcement earlier in the week - software sold off and set a sour mood - Microsoft dumped pretty hard as the amount of spend was higher than anticipated, especially with some slower growth in Azure. - Amazon took a beating on the increased spend they anticipate *(extra by $50B) - BUT: Friday markets rallied as there was realization that the $200B spend by Amazon would seep into the economy and fuel infrastructure spending along with chips, tech etc. Other Earnings of Interest -  Reddit reported fourth-quarter earnings on Thursday in which the social media company beat on the top and bottom lines. - The company said it expects first-quarter sales to come in the range of $595 million to $605 million, which is higher than Wall Street expectations of $577 million. - Reddit also announced a $1 billion share repurchase program. - Reddit gets about $250 million a year from OpenAi and Google to have your data for training their LLMs While we are on the subject - Friday, DJIA hit 50,000 - first time ever! - Up 1,200 point of which approx 350 was from caterpillar and 280 was from Goldman Sachs Hats off to WalMart - Walmart Inc. shares pushed its market capitalization past $1 trillion on Tuesday for the first time ever| - Big transformation over the pst year - Walmart has maintained its appeal to households looking for value, its online offerings are drawing new, wealthier shoppers seeking convenience. Google Bond Offering - Issuing several tranches of bonds, denominated in Stirling - one as long as 100 years - Would you buy that? - The Google parent is set to raise $20 billion from a US dollar bond offering on Monday — more than the $15 billion initially expected — and is also pitching investors on what would be its first ever offerings in Switzerland and the UK. - The latter would include a rare sale of 100-year bonds, the first time a tech company has tried such an offering since the dotcom frenzy of the late 1990s Fat Profits in Dietville - Really interesting sequence of events happening... - Hims launches compounded pill at prices as low as $49 per month - Analysts cite questions on efficacy, legality of pill - Hims' move shifts focus from Novo's strong Wegovy pill launch - Broader obesity market whipsawed as pricing pressure rises THEN.. - Hims and Hers Health shares dive 14% after hours on Friday (Down 25% on Monday) - FDA cites concerns over quality, safety, federal law - The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers, for its $49 weight-loss pill, including restricting access to the drug's ingredients and referring the company to the Department of Justice for potential violations of federal law. AND.... - Eli Lilly last Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. - The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. - Meanwhile, NOVO had a really bad outlook that took the shares down 13% after the report. Japan Markets Soar - Japanese stocks jumped to a record high Monday, leading gains in the region after Prime Minister Sanae Takaichi won a landmark election victory. - The ruling Liberal Democratic Party captured a two-thirds supermajority in the 465-seat lower house, public broadcaster NHK reported. - Japan's Nikkei 225 jumped past 57,000 for the first time before paring gains to close 3.9% higher at 56,363.94, while the Topix also notched a record high, closing at 3,783.94, up 2.3%. Employment Report? - Government shutdown is forcing them to postpone again (Which is dumb) - Number due this Wednesday - Maybe because of this:U.S. employers announced 108,435 layoffs for the month, up 118% from the same period a year ago and 205% from December 2025. The total marked the highest for any January since 2009. - At the same time, companies announced just 5,306 new hires, also the lowest January since 2009, which is when Challenger, Gray & Christmas began tracking such data. - Also, job openings fell sharply in December to 6.54 million, to their lowest since September 2020. - Available jobs are down by more than 900,000 just since October. - NO! Ai and advancements in tech have noting to do with this! NO NO NO M&A - Texas Instruments Inc. has reached an agreement to buy Silicon Laboratories Inc. for about $7.5 billion, deepening its exposure to several markets for chips. - Silicon Labs investors will receive $231 in cash for each share of the company's common stock and the transaction is expected to close in the first half of 2027. - The transaction still needs to win approval by investors in Silicon Labs and shares of Silicon Labs surged by 51% to $206.48 after the announcement. Inflation - This helps - PepsiCo (PEP.O), opens new tab will cut prices on core brands such as Lay's and Doritos by up to 15% following a consumer backlash against several previous price hikes, the snacks and beverage maker said on Tuesday after it topped fourth-quarter results. Miran - Moving - Federal Reserve Governor Stephen Miran is leaving his post as chair of the Council of Economic Advisers, CNBC has confirmed. - He joined the CEA in January 2025, but had been on leave from that post since last September when he filled the unexpired term of former Fed Governor Adriana Kugler.- He reamins on Fed board No Biggie???? - There are some astonishing cased being reported of Bad AI in the operating room - JNJ's TruDi Navigation System - Since AI was added to the device, the FDA has received unconfirmed reports of at least 100 malfunctions and adverse events. - At least 10 people were injured between late 2021 and November 2025, according to the reports. Most allegedly involved errors in which the TruDi Navigation System misinformed surgeons about the location of their instruments while they were using them inside patients' heads during operations. - Cerebrospinal fluid reportedly leaked from one patient's nose. In another reported case, a surgeon mistakenly punctured the base of a patient's skull. In two other cases, patients each allegedly suffered strokes after a major artery was accidentally injured. Cuba - The main airport has putt out a bulletin that they are out of Jet Fuel - Blackouts and lack of other fuels are creating big problems - No airlines have stopped running at this point, but many will as they cannot refuel - This is a bigger problem for cargo planes (supplies) that may not be able to risk flying to Cuba as they will not be able to get out. Love the Show? Then how about a Donation? ANNOUNCING THE WINNER OF THE THE CLOSEST TO THE PIN CUP 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!     FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Would you believe that there's a medication that can quiet the constant mental chatter around food for the first time in your adult life, but it could also cause you to lose muscle, age your face, and trap you in a cycle that's hard to escape? Both of those are true. When a drug can help someone lose 50 pounds and get off diabetes medication, that's a miracle. But when that same drug leaves someone unable to eat, losing muscle, and facing a lifetime of injections just to maintain their weight—that's a conversation we truly need to have. So, today we're taking a deep dive into GLP-1s—Ozempic, Wegovy, Mounjaro, and what's coming next. How to preserve muscle when taking GLP-1 medications Consume 1.2–1.6 g of protein per kilogram of body weight daily, spread across meals  Try to eat something containing 25–30 grams of protein within about two hours after doing a strength workout Consume easily digestible protein sources when your appetite is low (shakes, yogurt, collagen, or bone broth) Commit to doing resistance training at least two to three times a week Monitor your body composition for any early signs of muscle loss  Bio: Stephanie Gray Stephanie Gray, DNP, MS, ARNP, AGNP-C, ABAAHP, FAARFM, is a functional medicine provider helping men and women build sustainable, optimal health and longevity. A nurse practitioner since 2009, Dr. Gray completed her doctorate focusing on estrogen metabolism from the University of Iowa in 2011 and holds a Master's in Metabolic Nutritional Medicine from the University of South Florida's Medical School. Dr. Gray is one of the Midwest's most credentialed female healthcare providers. She completed an Advanced Fellowship in Anti-Aging, Regenerative, and Functional Medicine in 2013 and became Iowa's first BioTe certified provider—now the state's only platinum provider with over 10,000 pellet placements. She is also certified as a SIBO doctor-approved practitioner, mold-literate provider, and ReCODE 2.0 practitioner for cognitive decline prevention. An Amazon best-selling author, Dr. Gray wrote Your Longevity Blueprint and Your Fertility Blueprint, and hosts the Your Longevity Blueprint podcast. She co-founded Your Longevity Blueprint Nutraceuticals with her husband, Eric. After her own ten-year fertility journey, she now specializes in helping couples optimize reproductive health through functional medicine. Having lost her grandmother to vascular dementia, she is personally committed to helping families avoid cognitive decline. Dr. Gray founded the Integrative Health and Hormone Clinic in Hiawatha, Iowa. In this episode: How muscle preservation becomes non-negotiable when your appetite is suppressed Why protein timing matters more than total calories when on GLP-1 medications The importance of resistance training when taking GLP-1s The value of in-body scans for catching any muscle loss that may be occurring early on Why tapering off GLP-1 medications starts on day one, not at the finish line How natural GLP-1 stimulation can support or extend the effects of GLP-1 medications Why body composition, not weight loss, determines long-term outcomes when taking GLP-1s How the next generation of GLP-1 agonist drugs could improve our longevity Links and Resources: Relative Links for This Show: Use CODE BERBERINE to get 10% off ⁠⁠⁠Berberine  ⁠⁠⁠⁠⁠⁠Use Code FIBER to get 10% off GLP-1 Fiber Follow Your Longevity Blueprint  On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online   Follow Dr. Stephanie Gray  On Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast

GLP-1 medications like Ozempic and Wegovy are everywhere—and so are the opinions. In this episode, Andrew breaks down what GLP-1 actually is (a natural gut hormone), how GLP-1 medications work, and why newer “dual agonist” options like Mounjaro/Zepbound tend to produce bigger weight-loss results. We also tackle the controversy: is obesity a disease, and are GLP-1s “taking the easy way out”?You'll hear a coach's perspective from years in the trenches—why weight loss is effortless for some people and brutally hard for others, what typical results look like, common side effects, why many people stop, and what usually happens when you discontinue the meds.Chapters00:00 — Why GLP-1s are “big” right now01:12 — How common is obesity and GLP-1 use?05:20 — Obesity as a disease09:10 — The blame game12:40 — Are GLP-1's the easy way out?23:16 — GLP 101: what it is and what it does31:30 — Results, side-effects, and plateausThe Co-Movement Gym Podcast is supported by Native Path Supplements and Lombardi Chiropractic.

This Day in Legal History: Nelson Mandela ReleasedOn February 11, 1990, Nelson Mandela was released from Victor Verster Prison in South Africa after 27 years of incarceration, marking a seismic shift in the country's legal and political landscape. Mandela's release followed a period of secret negotiations between the apartheid government and the African National Congress (ANC), and it signaled the beginning of the end of apartheid—a system of institutionalized racial segregation and oppression upheld by law. His imprisonment had become a global symbol of the fight against racial injustice and was frequently challenged by international human rights organizations and legal scholars as a violation of fundamental human rights.Mandela had been convicted in 1964 of sabotage and other charges under South Africa's Suppression of Communism Act, following the infamous Rivonia Trial. He was sentenced to life imprisonment, spending much of his sentence on Robben Island under harsh conditions. Over the decades, growing international sanctions and internal unrest made apartheid increasingly untenable.Then-President F.W. de Klerk's government began rolling back apartheid legislation in the late 1980s, and on February 2, 1990, de Klerk announced the unbanning of the ANC and his intention to release Mandela. Just nine days later, Mandela walked free, delivering a speech in Cape Town that emphasized reconciliation, peace, and the continuation of the struggle for full democratic rights.Mandela's release was not just a political milestone—it was a legal one, too. It reflected a move away from laws based on racial supremacy and toward a constitutional order grounded in human rights. This transformation would culminate in South Africa's 1996 Constitution, often lauded for its rights-based framework and independent judiciary.The Trump administration's plan to repeal the EPA's 2009 endangerment finding—the scientific basis for regulating greenhouse gases under the Clean Air Act—could reignite legal efforts to hold polluters accountable through public nuisance lawsuits. That finding enabled the EPA to regulate emissions from vehicles and power plants, but its reversal removes the legal framework that had previously shielded companies from such claims under a 2011 Supreme Court ruling. In that decision, the Court held that the EPA's authority under the Clean Air Act displaced common-law nuisance suits against emitters. Without that EPA oversight, legal scholars believe plaintiffs may now argue that the courts are once again an appropriate venue for these claims.Public nuisance lawsuits, typically filed by states or municipalities, seek to hold companies accountable for harms caused to community health and safety. These cases have been historically difficult to win due to challenges in proving direct causation, but experts say the new regulatory gap could encourage a wave of litigation. Industry groups like the Edison Electric Institute have warned that repealing the endangerment finding could expose utilities to costly legal battles. While federal courts had largely blocked such claims, state courts have shown more openness, and the shift in federal policy may strengthen these legal efforts. Environmental advocates may now have renewed leverage to push power companies and other emitters into court.Trump's repeal of climate rule opens a ‘new front' for litigation | ReutersAttorney General Pam Bondi is scheduled to testify before the House Judiciary Committee this week amid intensifying legal scrutiny over the Justice Department's management of the Jeffrey Epstein files. Lawmakers are expected to question Bondi about what they view as excessive redactions and the DOJ's withholding of key documents, actions that may conflict with a bipartisan federal law passed in 2025 mandating the broad release of Epstein-related materials. Legal analysts suggest the DOJ's reliance on legal privileges—such as investigatory and deliberative process exemptions—to justify redactions could face stiff challenges in court or through congressional oversight powers.The situation raises constitutional tensions between legislative oversight and executive privilege, particularly as the House panel, now under Republican control, examines whether the DOJ is shielding politically sensitive information. Some members of Congress have accused the Department of undermining transparency and potentially violating the statutory intent of the Epstein Disclosure Act, which narrowed the DOJ's discretion in withholding records tied to convicted sex offenders or deceased suspects like Epstein.Bondi's DOJ has been accused of prioritizing partisan enforcement over institutional neutrality, illustrated by failed prosecutions of Trump critics and an aggressive posture on immigration and protest-related cases. The sidelining of the DOJ's civil rights division and the refusal to investigate federal shootings has further fueled concerns over selective enforcement and erosion of prosecutorial independence. Bondi's testimony will serve as a key moment to defend the Department's use of legal redactions and its broader approach to politically charged prosecutions.Bondi to face questions on Epstein files in House testimony | ReutersInstagram chief Adam Mosseri is set to testify in a Los Angeles courtroom this week in a groundbreaking lawsuit that could reshape how U.S. law approaches the intersection of product design and youth mental health. The case centers on a 20-year-old plaintiff who alleges she became addicted to Instagram as a child due to its deliberately addictive interface—particularly the “endless scroll” feature that loads content continuously to hold user attention. Her lawyers argue that Instagram's design choices amount to a form of negligent product engineering that failed to account for known risks to children.This case raises novel legal questions: Can user interface (UI) design be treated as a defective product under tort law? Can tech companies be held liable not just for content but for the architecture of the platforms themselves? If the court accepts these arguments, it could establish precedent for treating addictive design as a public health harm similar to tobacco or opioid marketing practices.Mosseri is expected to face questioning over internal documents that, according to the plaintiff, show Meta was aware of the app's mental health impact on vulnerable teens. Meta counters that these documents reflect efforts to mitigate harm, not evidence of negligence. Still, the case may test the limits of Section 230 immunity, as it focuses not on third-party content, but the platform's own design—potentially sidestepping the traditional legal shield for tech companies.Hundreds of similar cases are pending, and this trial may serve as a bellwether for litigation nationwide. International developments, including Australia's ban on social media for children under 16, suggest this is a growing legal frontier.Instagram's leader to testify in court on app design, youth mental health | ReutersNovo Nordisk's recent patent infringement lawsuit against Hims & Hers marks a pivotal legal development in the pharmaceutical industry's battle with telehealth providers distributing compounded drugs. The suit, filed in Delaware federal court, targets Hims' sales of compounded semaglutide—the active ingredient in Wegovy and Ozempic—claiming these formulations infringe Novo's patents. While compounding is allowed under certain FDA exemptions, those exemptions do not shield pharmacies or telehealth platforms from patent liability. This case challenges the assumption that FDA compliance protects against infringement claims, exposing a gray area where regulatory and intellectual property regimes collide.Historically, brand-name drugmakers focused on trademark challenges over how compounded drugs were marketed. Novo's move into patent litigation signals a strategic escalation: it's not about branding anymore—it's about the act of making and selling the compound itself. Experts highlight that this is likely the first time a brand drug company has pursued patent claims directly against a compounding pharmacy or telehealth distributor, suggesting the industry now sees these entities as substantial commercial threats.The case also underscores a novel enforcement strategy: suing the telehealth platform facilitating sales rather than the dispersed network of compounding pharmacies, streamlining legal action and potentially setting precedent for centralized liability. Hims, already under regulatory scrutiny, had just halted plans to sell compounded semaglutide pills but remains a target due to its involvement in injectable forms.The outcome of this case may clarify how FDA-sanctioned compounding intersects with patent protections and could define the boundaries for how far telehealth companies can go in offering customized versions of patented drugs.Novo's GLP-1 Patent Suit Against Hims Takes Aim at Compounding This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

GLP-1s like Ozempic and Wegovy are dominating the conversation around weight loss — but what happens when the prescription ends? In this episode, Shana sits down with Lindsay Venn, PA-C, RD, and Clinical Director of Insulin IQ, to unpack how to reverse metabolic dysfunction without relying on lifelong medication. They explore why insulin resistance is the real root issue, how to safely taper off GLP-1s without losing your progress, what labs can reveal your true healing status, and why many chronic diseases — including cancer — are deeply tied to your metabolism. This episode is a must-listen if you're struggling with fatigue, weight, hormonal chaos, or feeling like your body just isn't responding anymore. What We Covered: Why GLP-1s may help but not heal your metabolism The most important labs to run before tapering off Common mistakes when weaning off Ozempic & Wegovy How insulin, mitochondria, and inflammation connect to cancer The role of fasting insulin, meal timing, and light in true healing The #1 lifestyle shift to calm your hormones and burn fat naturally Links & Resources: Learn more about Lindsay: vennintegrativemedicine.com Reverse insulin resistance, fatty liver, and cholesterol issues: https://shanahussinwellness.com/fattyliverguide/ Join my 90-Day Insulin Reset: https://shanahussinwellness.com/programs-courses/reset/ Connect with Shana: Instagram: @shana.hussin.rdn Facebook: Shana Hussin Wellness

Today's episode features a very special guest, Peter Garnry, CEO and co-founder of Gesda Capital, as we discuss everything from Novo Nordisk's performance in the wake of its Wegovy pill release to nearly everything AI-adjacent, from the market's rough treatment of software-as-a-service names of late to the outlook for Mag7 stocks and hyperscalers on their massive AI capital spending arms race. We also look at the risks of passive investing, discuss the SpaceX IPO and much more. Hosting today's pod is Saxo Global Head of Macro Strategy John J. Hardy. Link: The Acquired podcast episode on Google: The AI Company that we referenced on the podcast.   Two or three times per week, you will also find links discussed on the podcast and a chart-of-the-day over at the John J. Hardy substack. Read daily in-depth market updates from the Saxo Market Call and the Saxo Strategy Team here. Please reach out to us at marketcall@saxobank.com for feedback and questions. Click here to open an account with Saxo. Intro and outro music by AShamaluevMusic DISCLAIMER This content is marketing material. Trading financial instruments carries risks. Always ensure that you understand these risks before trading. This material does not contain investment advice or an encouragement to invest in a particular manner. Historic performance is not a guarantee of future results. The instrument(s) referenced in this content may be issued by a partner, from whom Saxo Bank A/S receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.

Monday - We recap the Super Bowl from the Bad Bunny halftime show, commercials, snack food to the game itself. We get the latest on the Nancy Guthrie kidnapping. Gay Days suspended and Jimmy may be moving again. Dani Meyering covers for Deb while out. Attorney Ray Traendly on the Guthrie kidnapping, the Wegovy vs. Hims & Hers lawsuit and the Super Bowl. Plus, JCS News, Jack's Olympic Update, JCS Trivia & You Heard it Here First.

Monday - We recap the Super Bowl from the Bad Bunny halftime show, commercials, snack food to the game itself. We get the latest on the Nancy Guthrie kidnapping. Gay Days suspended and Jimmy may be moving again. Dani Meyering covers for Deb while out. Attorney Ray Traendly on the Guthrie kidnapping, the Wegovy vs. Hims & Hers lawsuit and the Super Bowl. Plus, JCS News, Jack's Olympic Update, JCS Trivia & You Heard it Here First. See omnystudio.com/listener for privacy information.

Send a textThis week on The Weekly Dose, Dave Knapp breaks down the biggest questions shaking up the GLP-1 world. From whether patients should be stocking up on compounded injectables, to what Eli Lilly's earnings call revealed about Zepbound QuickPens, refill rules, and the long-awaited retatrutide timeline, this episode covers it all. Dave also unpacks FDA enforcement signals, the escalating tension between Big Pharma and compounders, the Hims & Hers controversy, and what recent lawsuits and Super Bowl ads tell us about where obesity treatment is headed next. Clear context, real-world implications, and what patients should be discussing with their doctors right now.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

2025 marked the end of a four-year slide in series A financings for biotechs, with 144 biotechs raising an aggregate of $8 billion, up $1 billion from the prior two years. On the latest BioCentury This Week podcast, BioCentury's Danielle Golovin assesses which companies VCs backed last year and what their investments say about where technology is headed.Washington Editor Steve Usdin offers a perspective on why compounded Wegovy is an assault on the biopharma industry and also explains how the spending bill signed into law last week is a rebuke to proposed White House biomedical cuts.And Executive Editor Selina Koch unpacks her interview on The BioCentury Show podcast with neuroscientist and Seaport Chair Steven Paul, noting that while serendipity drives drug discovery in psychiatry, it's engineering that gets it across the finish line.View full story: https://www.biocentury.com/article/658367#BiotechFinancing #SeriesAFunding #VentureCapital #DrugDiscovery #BiopharmaPolicy00:00 - Introduction02:15 - Start-up Spotlight11:03 - Compounded Wegovy18:10 - Congress Rebuffs Trump Cuts23:50 - Steve Paul on NeuropsychiatryTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

A.M. Edition for Feb. 9. The latest revelations from the Epstein files bring down the top aide to Britain's Prime Minister. Will Keir Starmer be next? WSJ U.K. correspondent Max Colchester weighs in. Plus, Novo Nordisk shares are rallying after the U.S. Food and Drug Administration threatened to restrict access to the ingredients needed for knockoffs of popular GLP-1 medicines like WeGovy. And SpaceX delays its Mars plans to focus on the Moon instead. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Finding Freedom, host John Odermatt examines the rise of GLP-1 drugs like Ozempic and Wegovy, exploring how they work by overriding the body's natural hunger signaling through synthetic peptides inspired by Gila monster venom. While acknowledging these medications have legitimate applications for severe obesity and diabetes, John raises concerns about FDA-listed side effects including muscle loss, stomach paralysis, and thyroid tumor warnings, especially as Trump's new RX.gov platform makes these drugs more affordable and accessible. Drawing from his personal experience losing 50 pounds and maintaining the weight loss, John argues that synthetic GLP-1s don't address root metabolic dysfunction caused by poor diet, sedentary lifestyle, and chronic inflammation. He advocates for natural alternatives like berberine, chromium polynicotinate, and polydextrose fiber that support the body's own GLP-1 production rather than overriding it. John emphasizes the importance of building sustainable habits through diet, exercise, and supplementation that restore metabolic function instead of creating pharmaceutical dependency. The episode concludes with a call to prioritize long-term health over quick fixes, warning that rapid weight loss without muscle maintenance could lead to premature aging and sarcopenia. CHAPTERS: 0:00 - Introduction: GLP-1 Drugs Overview0:54 - Welcome & Episode Preview1:16 - Sponsor: Fox and Sons Coffee2:18 - John's Personal Weight Loss Journey4:49 - Trump RX.gov Announcement & Concerns10:22 - What is GLP-1? Understanding the Science13:46 - FDA-Listed Side Effects & Risks17:12 - Root Causes of Metabolic Dysfunction20:22 - Natural Alternative #1: Berberine22:32 - Natural Alternative #2: Chromium Polynicotinate23:34 - Natural Alternative #3: Polydextrose Fiber27:15 - Lifestyle Balance & Sustainable Habits30:29 - The Danger of Quick Fixes31:47 - Natural Supplements Recap & Resources34:45 - Final Thoughts & Call to Action36:33 - Support Lions of Liberty LINKS: John Odermatt on Twitter: @JohnOdermattJohn Odermatt on Instagram: @JohnOdermattEmail: John@LionsofLiberty.comNewsletter: https://john-odermatt-finding-freedom.kit.com/105b53c794Trump RX.gov: https://trumprx.gov SPONSOR: This episode is brought to you by Fox and Sons Coffee – fresh, high-quality coffee shipped directly to your door, available as whole bean or ground to your preference. Get 15% off orders of $40 or more with promo code JOHN at checkout.Visit: FoxNSons.com SUPPORT LIONS OF LIBERTY: Help keep this podcast going! We rely on listener support to continue bringing you content on health, freedom, and personal empowerment.Support us on Patreon: https://patreon.com/lionsoflibertySupport us on Locals: https://lionsofliberty.locals.com/Subscribe, rate, and review wherever you listen – it makes a huge difference! Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus: Shares in Novo Nordisk rally after the FDA clamps down on companies making compound versions of weight-loss drug Wegovy. And SpaceX delays a planned Mars mission to focus on Nasa's next moon landing. Daniel Bach hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Hong Kong media tycoon and vocal Beijing critic Jimmy Lai has been sentenced to 20 years in prison, President Trump has reversed his position on the Nexstar-Tegna broadcast TV deal, Hims & Hers has pulled its weight loss pill claiming to compete with Wegovy's obesity pill, Block may lay off 10% of its workforce, and Kroger could be planning to hire a former Walmart executive as its next CEO.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

National Economic Council Director Kevin Hassett discusses America's economic trajectory, including the jobs market and productivity, inflation, and President Trump's pick for new Fed chair, Kevin Warsh. Direct-to-consumer telehealth Hims & Hers made waves last month when it announced a cheaper, compounded obesity pill similar to Wegovy. Now, after the FDA warned against compounded GLP-1s, Hims & Hers is backing off. Former FDA Commissioner Dr. Scott Gottlieb discusses competition in obesity drugs, Novo Nordisk's lawsuit against Hims & Hers, and the importance of vaccines. Plus, the pharma and AI ads at Super Bowl LX, Japanese Prime Minister Sanae Takaichi secured a supermajority in a snap election, and CNBC's Emily Wilkins reports on the legislative efforts to address the U.S. housing affordability crisis. Emily Wilkins - 10:09Kevin Hassett - 19:21Dr. Scott Gottlieb - 30:10In this episode:Emily Wilkins, @emrwilkinsBecky Quick, @BeckyQuickJoe Kernen, @JoeSquawkAndrew Ross Sorkin, @andrewrsorkinCameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

MRKT Matrix - Monday, February 9th S&P 500 rises, led by tech; Dow climbs to fresh record (CNBC) Alphabet Embarks on Global Bond Spree to Fund Record Spending (Bloomberg) Alphabet Plans Tech's First 100-Year Bond Since Dot-Com Era (Bloomberg) Databricks completes $5 billion funding round at $134 billion valuation (CNBC) Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 17% (CNBC) FDA says Novo Nordisk's TV ad for obesity pill includes ‘false or misleading' claims (CNBC) China Urges Banks to Curb Exposure to US Treasuries (Bloomberg) Proposed Ban on Investors in the Housing Market Hits a Wall in Congress (WSJ) Job Hunters Are So Desperate That They're Paying to Get Recruited ⁠(WSJ)⁠ --- Subscribe to our newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://riskreversalmedia.beehiiv.com/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ MRKT Matrix by RiskReversal Media is a daily AI powered podcast bringing you the top stories moving financial markets Story curation by RiskReversal, scripts by Perplexity Pro, voice by ElevenLabs

In this episode of Finding Freedom, host John Odermatt examines the rise of GLP-1 drugs like Ozempic and Wegovy, exploring how they work by overriding the body's natural hunger signaling through synthetic peptides inspired by Gila monster venom. While acknowledging these medications have legitimate applications for severe obesity and diabetes, John raises concerns about FDA-listed side effects including muscle loss, stomach paralysis, and thyroid tumor warnings, especially as Trump's new RX.gov platform makes these drugs more affordable and accessible. Drawing from his personal experience losing 50 pounds and maintaining the weight loss, John argues that synthetic GLP-1s don't address root metabolic dysfunction caused by poor diet, sedentary lifestyle, and chronic inflammation. He advocates for natural alternatives like berberine, chromium polynicotinate, and polydextrose fiber that support the body's own GLP-1 production rather than overriding it. John emphasizes the importance of building sustainable habits through diet, exercise, and supplementation that restore metabolic function instead of creating pharmaceutical dependency. The episode concludes with a call to prioritize long-term health over quick fixes, warning that rapid weight loss without muscle maintenance could lead to premature aging and sarcopenia. CHAPTERS: 0:00 - Introduction: GLP-1 Drugs Overview0:54 - Welcome & Episode Preview1:16 - Sponsor: Fox and Sons Coffee2:18 - John's Personal Weight Loss Journey4:49 - Trump RX.gov Announcement & Concerns10:22 - What is GLP-1? Understanding the Science13:46 - FDA-Listed Side Effects & Risks17:12 - Root Causes of Metabolic Dysfunction20:22 - Natural Alternative #1: Berberine22:32 - Natural Alternative #2: Chromium Polynicotinate23:34 - Natural Alternative #3: Polydextrose Fiber27:15 - Lifestyle Balance & Sustainable Habits30:29 - The Danger of Quick Fixes31:47 - Natural Supplements Recap & Resources34:45 - Final Thoughts & Call to Action36:33 - Support Lions of Liberty LINKS: John Odermatt on Twitter: @JohnOdermattJohn Odermatt on Instagram: @JohnOdermattEmail: John@LionsofLiberty.comNewsletter: https://john-odermatt-finding-freedom.kit.com/105b53c794Trump RX.gov: https://trumprx.gov SPONSOR: This episode is brought to you by Fox and Sons Coffee – fresh, high-quality coffee shipped directly to your door, available as whole bean or ground to your preference. Get 15% off orders of $40 or more with promo code JOHN at checkout.Visit: FoxNSons.com SUPPORT LIONS OF LIBERTY: Help keep this podcast going! We rely on listener support to continue bringing you content on health, freedom, and personal empowerment.Support us on Patreon: https://patreon.com/lionsoflibertySupport us on Locals: https://lionsofliberty.locals.com/Subscribe, rate, and review wherever you listen – it makes a huge difference! Learn more about your ad choices. Visit megaphone.fm/adchoices

Wegovy is in the legal spotlight as lawsuits target “copycat” versions of the blockbuster drug — and we dig into how some medications become famous for side effects, like Viagra. (Spoiler: it was originally developed as a heart medication to treat chest pain/angina before its unexpected “other” effect changed everything. Then, we break down why the Super Bowl is still the most-watched, biggest revenue machine in American sports — and what makes it unmatched as an event. Plus, Super Bowl 60 security ramps up to a whole new level: a massive, coordinated operation with dozens of agencies working together and staying on high alert. And a fun SoCal tie-in: Seahawks QB Sam Darnold has roots in Capistrano Beach, California — and we talk about the local angle heading into the big game. See omnystudio.com/listener for privacy information.